Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-01

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

NCT01902186

HIV Infection Osteopenia

TERMINATED PHASE4

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

NCT02478632

HIV Infections

COMPLETED PHASE3

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

NCT01343225

HIV

UNKNOWN PHASE4

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

NCT00939874

HIV Osteopenia Osteoporosis +1 more

COMPLETED PHASE4

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802

HIV

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS HIV-1-infection Osteopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Switch

Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED\_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks

Group Type EXPERIMENTAL

Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)

Intervention Type DRUG

Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.

Continuation

Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.

Group Type ACTIVE_COMPARATOR

Current tenofovir alafenamide (TAF)-containing ART regimen

Intervention Type DRUG

Continuation of current TAF-containing ART for 96 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)

Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.

Intervention Type DRUG

Current tenofovir alafenamide (TAF)-containing ART regimen

Continuation of current TAF-containing ART for 96 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. HIV-1 infection, as documented by a positive 4th generation assay or by any licensed ELISA test kit confirmed by Western blot at any time prior to study entry.
2. Age ≥18 years
3. HIV-1 RNA BLQ (e.g., \<20 copies/mL or other threshold based on the local viral load assay used) for at least 12 months prior to study entry excluding blips (i.e., a single measurement \<200 copies/mL preceded and followed by measurements BLQ)
4. On a stable TAF-containing ART that also includes at least 2 other antiretrovirals, with no changes in the 12 months prior to entry (except for a switch to a co-formulated tablet from the component tablets or a switch from ritonavir to cobicistat)
5. Lumbar spine, femoral neck or total hip BMD T-score ≤-1.0 from a DXA scan within the past 48 weeks
6. If receiving testosterone or estrogen replacement therapy, on a stable dose for ≥3 months prior to enrollment without plan to change dose during the study period.
7. Acceptable blood laboratory values at screening visit:

* CD4+ T-cell count ≥200 cells/µL
* Phosphate ≥2mg/dL
* 25-hydroxyvitamin D level ≥10 ng/ml
* Calculated creatinine clearance (CrCl) ≥50 mL/min as estimated by the Cockcroft-Gault equation\*:

* For men = CrCl (mL/min) = (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dL x 72)

For women, multiply the above result by 0.85
8. For women of reproductive potential, negative serum or urine pregnancy test prior to screening and a negative urine pregnancy test at the entry visit prior to randomization and agreeable to using a contraceptive of choice during the study period.

"Women of reproductive potential" are defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) and have not undergone surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, or tubal ligation; participant report sufficient)

Exclusion Criteria

1. Current systemic glucocorticoid use
2. Lumbar spine, femoral neck or total hip BMD T-score \<-3.0
3. Previous, current pharmacologic treatment, or plan for initiation of therapy for osteoporosis (i.e., bisphosphonates, teriparatide, denosumab, tamoxifen or raloxifene)
4. Previous fragility fracture (i.e., any fall from a standing height or less that resulted in a fracture)
5. History of genotypic resistance or phenotypic resistance to either DTG or 3TC. The interpretation of genotypic resistance is based on output from the Stanford HIV Resistance Database (available at https://hivdb.stanford.edu). Isolates with an interpretation of low-level resistance or higher are considered resistant.
6. History of virologic failure (i.e., confirmed HIV-1 RNA level ≥200 copies/mL after over 6 months of therapy) while on an integrase inhibitor (i.e., raltegravir, elvitegravir, bictegravir, or dolutegravir) or on lamivudine/emtricitabine prior to study enrollment. Any antiretroviral history (even before routine virologic monitoring became standard of care) that would suggest the presence of the M184V mutation should be considered exclusionary
7. ALT ≥5 X ULN, OR ALT ≥3xULN and bilirubin ≥1.5xULN (with \>35% direct bilirubin)
8. Severe hepatic impairment (Child Pugh Class C)
9. Anticipated need for antiviral therapy for HCV
10. Hepatitis B surface antigen positive or Hepatitis B DNA positive
11. Weight \>300 pounds, precluding safe DXA testing
12. Breastfeeding, pregnancy, or plans to become pregnant during the study
13. Known allergy/sensitivity to DTG or 3TC.
14. Receipt or planned receipt of prohibited concomitant medications (See section 5.4)
15. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study procedures and treatment.
16. Any serious medical or psychiatric illness that, in the opinion of the site investigator, precludes safe participation or adherence to study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No